Don't get left behind! The modernized ClinicalTrials.gov is coming. Check it out now.
Say goodbye to ClinicalTrials.gov!
The new site is coming soon - go to the modernized ClinicalTrials.gov
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy and Safety of ARTISS for Flap Adherence in Abdominoplasty

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01112735
Recruitment Status : Completed
First Posted : April 28, 2010
Results First Posted : July 6, 2018
Last Update Posted : July 6, 2018
Sponsor:
Information provided by (Responsible Party):
Baxter Healthcare Corporation

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The purpose of the study is to compare the safety and efficacy of ARTISS versus standard of care in adhering tissue places and reducing seroma/hematoma formation in subjects undergoing abdominoplasty.

Condition or disease Intervention/treatment Phase
Seroma Hematoma Biological: FS VH S/D 4 s-apr (= two-component fibrin sealant, double virus inactivated, made from pooled human plasma) Procedure: Standard of care Phase 2

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Official Title: A Randomized, Controlled, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of ARTISS (FS VH S/D 4 S-apr) for Flap Adherence in Subjects Undergoing Abdominoplasty
Study Start Date : May 2010
Actual Primary Completion Date : December 2010
Actual Study Completion Date : February 2011
Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: ARTISS
ARTISS will be used as an adjuvant to standard of care.
 Biological: FS VH S/D 4 s-apr (= two-component fibrin sealant, double virus inactivated, made from pooled human plasma)
Dosage form: spray (aerosolized sealant), Dosage frequency: once (1 layer). ARTISS will be applied onto the fascia or the wound bed.
Other Name: ARTISS
Standard of care
Standard of care
 Procedure: Standard of care
Standard of care


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Total Drainage Volume Collected Until Drain Removal [ Time Frame: Day 0 (Surgery Day) to Day 90 ]
    Drainage fluids were to be collected through the Blake drain and into the collection bulb. The drainage volume was measured and recorded daily until the removal of the drain. During scheduled visits, measurement was to be performed at the study site, and on non-visit day recording of the drainage volume was to be done by a visiting home care nurse (or other study personnel). The drain was ready to be removed when the drainage volume in a given 24 hour period was <=30 cc.


Secondary Outcome Measures :
  1. Occurrence of Seroma [ Time Frame: Day 0 (Surgery Day) to Day 90 ]
    The investigator inspected each subject post surgery (Day 0) an each scheduled visit (Day 3, 7, 14, 28, 60, 90) to determine whether there were any areas on the abdominal wall that meet the definition of seroma. A seroma is a pocket of clear serous fluid that sometimes develops in the body after surgery. This fluid is composed of blood plasma that has seeped out of ruptured small blood vessels and inflammatory fluid produced by the injured and dying cells.

  2. Occurrence of Hematoma [ Time Frame: Day 0 (Surgery Day) to Day 90 ]
    The investigator inspected each subject post surgery (Day 0) an each scheduled visit (Day 3, 7, 14, 28, 60, 90) to determine whether there were any areas on the abdominal wall that meet the definition of hematoma. A hematoma is a collection of blood outside of a blood vessel.

  3. Time to Drain Removal [ Time Frame: Day 0 (Surgery Day) up to Day 90 ]
    The drain was ready to be removed when the drainage volume in a given 24 hour period was <=30cc.

  4. Number of Fluid Aspiration for Seromas [ Time Frame: Day 0 (Surgery Day) to Day 90 ]
    Number of interventions recorded.

  5. Total Volume of Fluid Aspirations for Seromas [ Time Frame: Day 0 (Surgery Day) to Day 90 ]
    Volume of fluid recovered was recorded.

  6. Change From Baseline in Postoperative Skin Sensitivity 2 Inches Above Umbilicus [ Time Frame: Days 0 (Baseline), 3, 7, 14, 28, 60, 90 ]

    Test administered on abdomen midline using a set of different size Semmes-Weinstein monofilaments. These instruments are used to measure the cutaneous sensory perception threshold of patients. Each monofilament represents a unique amount of force. The force applied by each monofilament increases with each ascending size. Testing begins with small to large monofilaments. A higher score indicates a greater loss of sensation. Evaluator Size=ES, Hand & Dorsal Foot Thresholds=HDFT, Normal=N, Diminished Light Touch=DLT,Diminished Protective Sensation=DPS, Loss of Protective Sensation=LOPS, Deep Pressure Sensation Only=DPSO:

    ES=1.65 (minimum),HDFT=N;ES=2.36,HDFT=N;ES=2.44,HDFT=N;ES=2.83,HDFT=N;ES=3.22,HDFT=DLT;ES=3.61,HDFT=DLT;ES=3.84,HDFT=DPS;ES=4.08,HDFT=DPS;ES-4.17,HDFT=DPS;ES=4.31,HDFT=DPS;ES=4.56,HDFT=LOPS;ES=4.74,HDFT=LOPS;ES=4.93,HDFT=LOPS;ES=5.07,HDFT=LOPS;ES=5.18,HDFT=LOPS;ES=5.46,HDFT=LOPS;ES=5.88,HDFT=LOPS;ES=6.10,HDFT=LOPS;ES=6.45,HDFT=LOPS;ES=6.65 (maximum),HDFT=DPSO.


  7. Change From Baseline in Postoperative Skin Sensitivity 1 Inch Below Umbilicus [ Time Frame: Days 0 (Baseline), 3, 7, 14, 28, 60, 90 ]
    Test administered on abdomen midline using a set of different size Semmes-Weinstein monofilaments. These instruments are used to measure the cutaneous sensory perception threshold of patients. Each monofilament represents a unique amount of force. The force applied by each monofilament increases with each ascending size. Testing begins with small to large monofilaments, pressing at a 90 degree angle for approximately 1.5 seconds against the skin until it bows then it is removed. The patient is instructed to respond when a stimuli is felt, and a score is applied based on the monofilament in use. A higher score indiactes a greater loss of sensation.

  8. Summary of Pain Assessment by Visit [ Time Frame: Day 3, 7, 14, 28, 60, 90 ]
    Subjects were to be presented with a non-verbal visual analogue scale (VAS) to measure the level of pain (rating 0 [no pain] to 10 [worst possible pain]) the patient experienced at the site of surgery at the time of the visit.

  9. Summary of Numbness Assessment by Visit [ Time Frame: Day 3, 7, 14, 28, 60, 90 ]
    Subjects were to be presented with a non-verbal VAS to measure the level of numbness (rating 0 [no numbness] to 10 [complete numbness]) that the patient experienced at the time of the visit.


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Subject is 18 to 75 years of age at the time of screening
  • Subject is planned for primary standard abdominoplasty (status post Cesarean section or liposuction performed more than 6 months prior to enrollment in the study are allowed)
  • If the subject is of childbearing potential; presents with a negative pregnancy test, and agrees to employ adequate birth control measures for the duration of the study
  • Subject resides within 100 miles of the investigational site and is willing and able to comply with the scheduling requirements of the protocol (notably home visits by study personnel)
  • Subject is willing and able to comply with the requirements of the protocol

Exclusion Criteria:

  • Subject is obese (body mass index [BMI] > 30 before surgery)
  • Subject has experienced massive weight loss (subject has a history of obesity during adult life; subject lost more than 20 BMI unit score, subject has undergone a bariatric surgery)
  • Subject has a history of active smoking within the previous 12 months
  • Subject is elected for a non-standard abdominoplasty (extended, limited or mini-abdominoplasty, endoscopic, fleur-de-lis or circumferential abdominoplasty) or panniculectomy
  • Subject has scars on the abdominal wall above the umbilicus. Vertical midline, laparoscopic punctures, or liposuction punctures are permitted
  • Subject is planned for other "body lifting" procedures (eg to the arms, legs, back etc.)
  • Subject is planned for combined abdominoplasty with other cosmetic procedures including liposuction (restricted liposuction of the waist line and the lower back is allowed, as long as the integrity of the surgical spaces is maintained)
  • Subject has an active or chronic skin disorder, history or evidence of keloid formation, or hypertrophic scarring
  • Subject has a history of gastrointestinal disorders (eg Irritable Bowel Syndrome) requiring prescription medications
  • Subject has a known abdominal hernia that requires mesh fixation
  • Subject has a documented hiatal hernia or acid reflux disease
  • Subjects with congenital or acquired immunodeficiency disorders
  • Subject has uncontrolled diabetes mellitus (HbA1c > 7.0)
  • Subject has a history of cardio-vascular disease including uncontrolled hypertension (> 140/90 mm Hg)
  • Subject has a clinically diagnosed psychiatric disorder (including obsessive compulsive disorders)
  • Subject has a known (documented) bleeding or coagulation disorder including history of thromboembolic events
  • Subject is being treated with anti-coagulants or with Aspirin (that was not discontinued 7 days prior to surgery)
  • Subject is receiving active treatment for a malignancy
  • Subject has a connective tissue disorder
  • Subject has received chronic treatment with immunosuppressive drugs, systemic corticosteroids, or other chronic treatments within 30 days prior to the surgery
  • Subject has participated in another clinical study involving an investigational product (IP) or investigational device within 30 days prior to enrollment or is scheduled to participate in another clinical study involving an IP or investigational device during the course of this study
  • Subject has a known sensitivity to fibrin sealants
  • Subject is a friend, employee, or relative of the investigator or other study personnel
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01112735


Locations
Layout table for location information
United States, California
Mei Li Surgery Center
Beverly Hills, California, United States, 90210
United States, Florida
Center for Plastic Surgery and Skin Care
Fort Lauderdale, Florida, United States, 33308
Miami Plastic Surgery
Miami, Florida, United States, 33176
United States, Georgia
Places Plastic Surgery
Atlanta, Georgia, United States, 30327
United States, Illinois
The Practice of Gary Wiesman, M.D. and Irvin Wiesman, M.D. and Associates
Chicago, Illinois, United States, 60654
United States, Texas
UT Southwestern Medical Center, Department of Plastic Surgery
Dallas, Texas, United States, 75390-9132
Sponsors and Collaborators
Baxter Healthcare Corporation
Investigators
Layout table for investigator information
Study Director: Steve Z Abrams, MD, MBA Baxter Healthcare Corporation
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Baxter Healthcare Corporation
ClinicalTrials.gov Identifier: NCT01112735    
Other Study ID Numbers: 550902
First Posted: April 28, 2010    Key Record Dates
Results First Posted: July 6, 2018
Last Update Posted: July 6, 2018
Last Verified: June 2018
Keywords provided by Baxter Healthcare Corporation:
Abdominoplasty
Flap adherence in subjects undergoing abdominoplasty to eliminate dead space and reduce seroma/hematoma formation
Additional relevant MeSH terms:
Layout table for MeSH terms
Hematoma
Seroma
Hemorrhage
Pathologic Processes
 Inflammation
Fibrin Tissue Adhesive
Hemostatics
Coagulants